News Tysabri failure in stroke a setback for Biogen Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed.
News Novartis/Amgen migraine drug reduces attacks after others fa... Aimovig notches up another late-stage trial success
News Regeneron: Biobank project offers hope for Alzheimer's R&D Regeneron R&D chief hopes UK data could find new Alzheimer's and Parkinson's drugs
News Roche's Ocrevus MS drug approved in EU Already a big hit in the US, Ocrevus set to make debut in EU.
News Bad week for dementia R&D after Axovant howler and another f... Axovant misreports trial results, Lundbeck Alzheimer's drug fails
News Axovant axes dementia drug after disastrous trial results Intepirdine seemed to make symptoms worse in Lewy body disease
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.